BioCentury | Mar 16, 2020
Politics, Policy & Law

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

Biopharma executives rebuked Sen. Bernie Sanders (I-Vt.) for attacking them and the biopharmaceutical industry Sunday evening during a debate with former Vice President Joe Biden. Science, not politics, will defeat COVID-19, industry leaders told BioCentury....
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

Sunday was International Women’s Day. I looked back at a column I wrote in 2018 wondering how much of it was still relevant. Can something as fundamental as the situation for women in our industry...
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

Responding to Belcher Pharmaceuticals' use of the Orphan Drug pathway to support price hikes on an old drug, a group of pharma CEOs have raised concerns in an open letter that this type of behavior...
BC Extra | Oct 26, 2019
Company News

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe  The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The oral...
BC Extra | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

Sirtex Medical Ltd. (ASX:SRX) named Kevin Smith CEO. He was interim CEO and, before that, the cancer therapy company's EVP, sales & marketing for the Americas. Prior to joining Sirtex, Smith was EVP of business...
BC Extra | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

Novartis’ Eylea competitor approved  FDA approved Beovu brolucizumab-dbll from Novartis AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER trials, the anti-VEGF single-chain antibody fragment led to vision...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

Mark Schoenebaum, an admired biopharma equity analyst, died over the weekend. Schoenebaum resigned as senior managing director and head of healthcare/biotech & pharma equity analyst at Evercore ISI in 2017. Prior to joining Evercore in...
BC Extra | Aug 22, 2019
Politics & Policy

Biomedical stakeholders caution against limiting U.S.-China collaboration

A group of nearly 150 U.S. academics and biomedical research and drug development stakeholders warned that actions which create a climate of fear or limit international collaboration between U.S. and Chinese scientists could jeopardize U.S....
BC Extra | Aug 2, 2019
Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

FDA approves Daiichi's pexidartinib  FDA approved Turalio pexidartinib from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat tenosynovial giant cell tumor. A Daiichi spokesperson told BioCentury the drug has been launched at a wholesale acquisition cost...
Items per page:
1 - 10 of 565
BioCentury | Mar 16, 2020
Politics, Policy & Law

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

Biopharma executives rebuked Sen. Bernie Sanders (I-Vt.) for attacking them and the biopharmaceutical industry Sunday evening during a debate with former Vice President Joe Biden. Science, not politics, will defeat COVID-19, industry leaders told BioCentury....
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

Sunday was International Women’s Day. I looked back at a column I wrote in 2018 wondering how much of it was still relevant. Can something as fundamental as the situation for women in our industry...
BioCentury | Feb 20, 2020
Politics, Policy & Law

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

Responding to Belcher Pharmaceuticals' use of the Orphan Drug pathway to support price hikes on an old drug, a group of pharma CEOs have raised concerns in an open letter that this type of behavior...
BC Extra | Oct 26, 2019
Company News

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe  The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The oral...
BC Extra | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

Sirtex Medical Ltd. (ASX:SRX) named Kevin Smith CEO. He was interim CEO and, before that, the cancer therapy company's EVP, sales & marketing for the Americas. Prior to joining Sirtex, Smith was EVP of business...
BC Extra | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

Novartis’ Eylea competitor approved  FDA approved Beovu brolucizumab-dbll from Novartis AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER trials, the anti-VEGF single-chain antibody fragment led to vision...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

Mark Schoenebaum, an admired biopharma equity analyst, died over the weekend. Schoenebaum resigned as senior managing director and head of healthcare/biotech & pharma equity analyst at Evercore ISI in 2017. Prior to joining Evercore in...
BC Extra | Aug 22, 2019
Politics & Policy

Biomedical stakeholders caution against limiting U.S.-China collaboration

A group of nearly 150 U.S. academics and biomedical research and drug development stakeholders warned that actions which create a climate of fear or limit international collaboration between U.S. and Chinese scientists could jeopardize U.S....
BC Extra | Aug 2, 2019
Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

FDA approves Daiichi's pexidartinib  FDA approved Turalio pexidartinib from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat tenosynovial giant cell tumor. A Daiichi spokesperson told BioCentury the drug has been launched at a wholesale acquisition cost...
Items per page:
1 - 10 of 565